Updated:
Cytosorbents Corp
Cytosorbents Corp is a publicly traded medical device company — not a family office, asset manager, or capital allocator — listed on NASDAQ under CTSO.
Cytosorbents Corp
Cytosorbents Corp is a publicly traded medical device company listed on NASDAQ under the ticker CTSO. The firm is not a family office, asset manager, or any form of capital allocator. It develops and commercializes a blood purification technology called CytoSorb, designed to reduce excessive inflammatory mediators during life-threatening conditions such as sepsis, cardiac surgery, and acute respiratory distress. The company operates a single-product platform sold globally to hospitals through direct sales and distribution partners. Its revenue comes from cartridge sales, not from managing third-party capital. There are no fund commitments, direct investments, co-investment structures, or allocation strategies. Cytosorbents reports its financials publicly via SEC filings. It has no known affiliated family office vehicles, philanthropic foundations, or investment partnerships. The firm's employee base consists of scientists, engineers, and commercial staff rather than investment professionals. Recent operational history involves regulatory submissions and clinical trial milestones rather than fundraising closes or deployment activity. Structurally, Cytosorbents is a healthcare manufacturer with no family-office architecture, no succession-driven governance for wealth management, and no capital deployment vehicle. It is an operating business that generates revenue through product sales, not an entity that allocates capital on behalf of a family or external limited partners.
General information
Firm type
Asset Manager
Year founded
—
AUM
Undisclosed
Location
Region
—
Country
—
City
—
Corporate office
—
Frequently asked questions
Is Cytosorbents Corp a family office or asset manager?
No. Cytosorbents Corp is a publicly traded medical device company (NASDAQ: CTSO) that manufactures blood purification cartridges. It is not an investment firm, does not manage third-party capital, and has no family office structure. Its classification as an asset manager appears to be a data error.
What does Cytosorbents Corp actually do?
The company developed and sells CytoSorb, a blood purification cartridge that removes cytokines and other inflammatory mediators from blood during life-threatening conditions like sepsis, cardiac surgery, and respiratory failure. It earns revenue through cartridge sales to hospitals worldwide rather than through any investment activity.
Does Cytosorbents Corp deploy capital into private markets?
No. As an operating medical device company, Cytosorbents deploys its capital toward research and development, regulatory approvals, clinical trials, and commercial expansion of its single-product platform. It does not make fund commitments, direct investments, or co-investments.
Who runs Cytosorbents Corp?
The company is led by a management team and board typical of a publicly traded medical device firm, with executive leadership focused on clinical and commercial operations rather than investment management. Specific current principals can be confirmed via SEC filings and the company's investor relations page.
Why is Cytosorbents Corp listed in an allocation database?
This profile exists to correct a likely classification error. Cytosorbents Corp is a medical device manufacturer, not a family office, asset manager, or institutional allocator. No evidence supports its categorization as an investment entity.
Profile maintained by Altss using OSINT (open-source intelligence), regulatory filings, licensed data partners, and verified direct submissions. Read the methodology. Last updated: . Continuous refresh with full update cycles at least every 30 days.
Need institutional-grade insight on family offices?
Altss delivers:
Prefer a guided tour?
We’ll walk you through: